AUSTRALIA- Leading Australian biopharmaceutical company Luina Bio has rebranded to AcuraBio following its acquisition by Dr. Glenn Haifer and global healthcare private equity firm Ampersand Capital Partners.
AcuraBio is a company with more than 20 years of experience that markets cutting-edge treatments for clients in the biotech, pharmaceutical, and animal health sectors.
Recombinant proteins, vaccines, complicated live biotherapeutic solutions, and more are offered by AcuraBio to clients who are at the forefront in the field of new treatments.
AcuraBio’s rebranding heralds the beginning of an innovative new growth phase. Dr. Haifer and Ampersand are bringing a sizable investment to the company as part of the deal, with an emphasis on growing the business to better serve clients.
The newly rebranded company intends to expand the capacity of its production facilities in order to support further growth.
The company is also actively considering the expansion of its service offerings and technological capabilities.
AcuraBio is perfectly positioned in Australia to facilitate global biopharmaceutical drug development, according to David Anderson, General Partner of Ampersand.
Dr. Haifer brings a wealth of experience to AcuraBio, as the former company Chairman and investor behind Australian biotech successes such as Agilex Biolabs and Avance Clinical.
“We are very excited to be reinventing a company with such deep scientific experience,” said Dr. Haifer.
“With our deep expertise and commitment to further investment, AcuraBio will be a leader in the APAC region for international biopharma clients attracted by the technology, scientific excellence, and innovation we will bring to the platform.
He mentioned that he is excited to leverage Ampersand’s industry expertise as they take AcuraBio to the next level.
Ampersand, a US-based company that manages more than US$3 billion in assets, focuses solely on growth-oriented investments in the healthcare industry.
The firm is a highly seasoned investor in the developing pharmaceuticals CDMO market.
The company has previously partnered with top CDMOs like Brammer Bio, ArrantaBio, Vibalogics, and Genezen.
AcuraBio is perfectly positioned in Australia to facilitate global biopharmaceutical drug development, according to David Anderson, General Partner of Ampersand.
Worldwide biopharma enterprises can benefit from AcuraBio’s strong quality, cost, and intellectual property assurances.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
